OraSure Technologies INVESTOR PRESENTATION JULY 2020 DNAgenoTeK" % Diversigen" novosanis Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are ...

Financial Data and Key Metrics Changes - Net revenues for Q1 2020 were $31.6 million, a 5% increase from $30.1 million in Q1 2019. Excluding the cryosurgical product line sold in 2019 and including Diversigen's contribution, revenues grew 8% [17][22] - The net loss for Q1 2020 was $7.3 million or $0.12 per share, compared to a net loss of $3.3 million or $0.05 per share in Q1 2019 [29] - Cash balances at the end of Q1 2020 totaled $176 million, providing a strong liquidity position to navigate uncertainties [21][30] Business Line Data and Key Metrics Changes - International HIV sales increased 74% to $6.9 million, driven by strong demand for HIV Self-Tests [18][23] - Domestic HIV sales decreased 2% to $4.2 million due to COVID-19 impacts on public health testing [23] - Domestic HCV sales decreased 18% to $1.5 million, while international HCV sales decreased 25% to $1.1 million [24] - Molecular revenues increased 16% to $13.8 million, with genomic product revenues growing 14% to $9.1 million [25][46] Market Data and Key Metrics Changes - The COVID-19 pandemic has caused delays in HIV and HCV testing programs, impacting domestic sales [13][24] - Increased sales of In-Home HIV tests were noted as public health strategies adapted to COVID-19 [14][38] - The molecular solutions segment saw a 25% revenue increase, attributed to a shift from blood to saliva collection due to COVID-19 [46][50] Company Strategy and Development Direction - The company is focusing on developing COVID-19 testing products, including a pan-SARS coronavirus rapid antigen in-home self-test and an oral fluid microplate test for antibodies [9][41][44] - The strategy includes leveraging existing capabilities in infectious disease diagnostics to address COVID-19 testing needs [8][64] - The company is exploring collaborations to expand production capacity and meet high demand for COVID-19 products [45][55] Management's Comments on Operating Environment and Future Outlook - Management acknowledged mixed impacts from COVID-19, with some revenue pressures but also new opportunities arising from increased demand for testing [11][31] - The company remains optimistic about the growth of its HIV Self-Testing business and the potential for new COVID-19 products to drive future revenues [64][65] - The management has withdrawn financial guidance for 2020 due to uncertainties related to the pandemic [31] Other Important Information - The company has implemented enhanced hygiene and social distancing protocols to ensure employee safety during the pandemic [12] - A significant organizational change was announced, with a new leader for the infectious disease business unit set to join [59][60] - The company is integrating its microbiome laboratory businesses and relocating to a new facility to enhance operational efficiency [57][58] Q&A Session Summary Question: Sensitivity and specificity of the rapid test - Management indicated a history of achieving high sensitivity and specificity in their product portfolio, with ongoing development for the new rapid test [68][69] Question: Pricing strategy for the home test - Management noted that pricing strategies are still under consideration and will be informed by their experience in the HIV market [72][73] Question: Manufacturing capacity for tests - Management discussed the need for significant capacity increases to meet potential demand for COVID-19 tests, with current production capabilities in the tens of millions of tests per year [74][75] Question: COVID-19 situation in sub-Saharan Africa - Management highlighted the importance of continuing HIV testing in Africa amidst COVID-19 and the potential for synergies in sales channels for both HIV and COVID-19 tests [78][81] Question: Future positioning of the company - Management expressed a vision of evolving into a broader infectious disease company, leveraging learnings from COVID-19 to address future public health needs [82][85] Question: Overall outlook considering COVID-19 impacts - Management sees more strength in tailwinds than headwinds, with optimism about the growth of the COVID-19 related business despite some negative impacts [88][89]

Financial Data and Key Metrics Changes - Q4 2019 net revenues were $49.7 million, a decrease of 1% from $50.2 million in Q4 2018, marking the third highest revenue quarter in the company's history [9][13] - Net product and services revenues increased by 5% to $47.2 million compared to the prior year period, excluding cryosurgical revenue from Q4 2018, which would result in a 12% increase in product and service revenue for Q4 2019 [13][19] - GAAP EPS for Q4 2019 was $0.04, down from $0.16 in Q4 2018, with net income of $2.4 million compared to $10.3 million in the same period last year [19][41] - Cash and investments balance at December 31, 2019, was $189.8 million, down from $201.3 million at the end of 2018 [19] Business Line Data and Key Metrics Changes - International HIV sales increased by 123% to $9.8 million in Q4 2019, contributing to a 37% increase in infectious disease testing revenue compared to 2018 [10][13] - Microbiome revenues more than doubled in Q4 2019 compared to 2018, reaching $4.4 million, primarily due to contributions from newly acquired subsidiaries [10][16] - Molecular revenues decreased by 8% to $27.8 million in Q4 2019, with royalty income declining by 55% to $2.2 million [15][19] Market Data and Key Metrics Changes - Domestic HCV sales increased by 7% to $2.2 million in Q4 2019, while international HCV sales decreased by 19% to $1.3 million [13][14] - The microbiome market is experiencing double-digit sales growth, with a 13% increase in first-time kit purchasers in Q4 2019 compared to the previous quarter [28][29] Company Strategy and Development Direction - The company advanced its innovation growth strategy through acquisitions of microbiome laboratory services pioneers, enhancing product and service offerings [6][12] - The divestiture of the cryosurgery systems product line was aimed at better aligning with high-priority growth opportunities [6][12] - The company is focusing on expanding its presence in the disease risk management submarket, which is expected to grow at a rate of 7% to 10% per year [25][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the infectious disease and molecular segments, despite ongoing challenges in the consumer genomics market [12][41] - The company expects high-teens growth in its global HIV franchise and strong growth from global HCV in 2020, alongside triple-digit growth from microbiome services [20][45] - Management highlighted the importance of regulatory approvals and customer contracts in driving future growth [27][36] Other Important Information - The company recorded a decline in gross profit percentage to 60% in Q4 2019 from 69% in Q4 2018, attributed to a product mix shift [16] - The company is exploring additional development opportunities to expand its product portfolio into new sample types and analytes [33] Q&A Session Summary Question: 2020 outlook and guidance process - Management did not approach the guidance process differently but included expectations around end-of-quarter shipments affecting total revenues [44] Question: Clarification on large customer contract - The contract has been extended to the end of 2023, with expectations for growth from the new annual minimum in 2020 [47][48] Question: 2020 guidance conservatism and revenue phasing - The guidance reflects a rebuilding year with expectations for significant growth post-2020, and revenue phasing is expected to mirror 2019 [51][52] Question: HIV Self-Test registrations and scaling - The company is in a stronger position to scale in existing countries with registrations already in place, and they are tracking well towards margin goals without subsidies [59] Question: M&A revenue contribution in Q4 - Acquisitions contributed $5.2 million for the full year, with no specific quarterly breakdown provided [65] Question: Accounts receivable spike in Q4 - The spike was due to end-of-quarter shipments, which increased accounts receivable [66]

OraSure Technologies Inc. (NASDAQ:OSUR) Q3 2019 Earnings Conference Call November 6, 2019 5:00 PM ET Company Participants Stephen Tang - President and Chief Executive Officer Roberto Cuca - Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies John Hsu - Raymond James Operator Good afternoon, everyone and welcome to the OraSure Technologies 2019 Third Quarter Financial Results Conference Call and Simultaneous Webcast. As a reminder, todayÂ's conference is being recorded. [Operat ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q2 2019 Earnings Conference Call August 6, 2019 5:00 PM ET Company Participants Stephen Tang - President and Chief Executive Officer Roberto Cuca - Chief Financial Officer Conference Call Participants Max Masucci - Canaccord Genuity Limited John Hsu - Raymond James & Associates, Inc. Brandon Couillard - Jefferies & Company, Inc. Operator Good afternoon, everyone, and welcome to the OraSure Technologies 2019 Second Quarter Financial Results Conference Call and Simulta ...

OraSure Technologies UBS Global Healthcare Conference May 22, 2019 OraSure Technologies, Inc. SMIL Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including statements with respect to revenues, earnings, technology, new products, product performance, markets, clinical development, regulatory filings and approvals, and business plans. Factors affecting these statements include, but are not limited to, the ability to develop new technology, t ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q1 2019 Earnings Conference Call May 8, 2019 5:00 PM ET Company Participants Stephen Tang - President & CEO Roberto Cuca - CFO Conference Call Participants Max Masucci - Canaccord Genuity Operator Good afternoon, everyone, and welcome to the OraSure Technologies 2019 First Quarter Financial Results Conference Call and Simultaneous Webcast. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After th ...